There have been no reports of illness or adverse reactions from consumption of the recalled burritos, but FSIS recommends ...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

An announcement from NFI Group Inc ( ($TSE:NFI) ) is now available. NFI Group Inc. and GILLIG LLC have formed a 50/50 joint venture to acquire the ...

Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

BioArctic AB's (publ) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a ...

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth . Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

SAIC Director and Seasoned Government Services Executive James Reagan Appointed Interim CEOCompany Reaffirms Fiscal Year 2026 ...

SAIC said Reagan, who has served on the SAIC board since 2023, most recently was finance chief at Leidos Holdings, and previously was chief financial officer at Vencore, PAE and Aspect Communications.

SAIC Director and Seasoned Government Services Executive James Reagan Appointed Interim CEOCompany Reaffirms Fiscal Year 2026 GuidanceRESTON, Va., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Science Application ...

NFI Group Inc. (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) and GILLIG LLC, today announced that the companies have formed a 50/50 ...